Drug Trial Radar · NCT07198321
A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Sep 18, 2025
Primary completion
Jul 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Genfleet Therapeutics (Shanghai) Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an investigation to evaluate the safety/tolerability, pharmacokinetics (PK), and efficacy of GFH276 as a single agent in patients with advanced solid tumors harboring RAS mutations. The primary objectives of the Phase I study are to assess the safety/tolerability, PK, and preliminary efficacy of GFH276 in patients with advanced solid tumors harboring RAS mutations, and to determine the Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of GFH276. The primary objective of the Phase II study is to evaluate the efficacy of GFH276 in patients with RAS-mutant advanced pancreatic ductal adenocarcinoma (PDAC), advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC), and other advanced solid tumors.
Conditions
- Cancer
- PDAC
- CRC (Colorectal Cancer)
- NSCLC
Interventions
GFH276Drug
GFH276 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia:The incidence and severity of AEs and SAEsTime frame: 48 months
- Phase Ia:The incidence of DLT eventsTime frame: 21 days
- Phase Ib:The incidence and severity of AEs and SAEsTime frame: 48 months
- Phase II:Overall response rate (ORR)Time frame: about 48 months
- Efficacy endpointsTime frame: about 48 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun-Yat sen university cancer center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.